Description
Yohimbinos 2.5 mg Driada Medical — Manufactured to exacting pharmaceutical standards, this pharmaceutical-grade thermogenic compound accelerates fat metabolism and supports lean body composition during cutting phases. Enhances metabolic rate while preserving lean muscle tissue. This formulation is dosed at 2.5 mg per unit.
Key Benefits
- α2-adrenergic antagonist — blocks fat-cell inhibitory signalling
- Targeted fat mobilisation in stubborn areas (lower abdomen, hips)
- Fasted-state dosing for maximum effect
- Oral once-daily; anxiety-prone users should avoid
- Standalone or stacked with clenbuterol for aggressive cutting
- Each unit dosed at 2.5 mg — see Recommended Dosage below for protocol-specific intake
How It Works
α2-adrenergic receptor antagonist. α2 receptors on adipocytes inhibit lipolysis — blocking them un-caps fat mobilisation, especially in “stubborn” fat depots (lower body, abdomen) that are α2-dense. Fasted state amplifies effect because insulin blunts lipolysis.
Pharmacokinetics
Plasma half-life approximately 36 minutes — short burst effect. Pre-workout dosing only. Oral bioavailability moderate.
Potential Side Effects
Anxiety, jitteriness, blood-pressure spikes. Not for anxiety-prone users. Avoid with SSRIs, MAOIs, or caffeine overload. Tachycardia during workout normal but monitor.
Cycle & Stacking Guide
Pre-fasted-cardio dosing during cutting phases, 4–6 weeks. Stack with caffeine (with tolerance) or clenbuterol for aggressive fat-loss. Not a mass-phase compound.
Manufacturer Notes
Driada Medical positions itself at the affordable end of the market while maintaining third-party lab verification. Their vial caps carry a tamper-seal date code; batch COAs available through the distributor.
Storage & Handling
Store at recommended temperature (15–25°C; peptides and HGH at 2–8°C after reconstitution). Protect from light and moisture. Keep out of reach of children. For research and educational purposes only.
Reviews
There are no reviews yet.